Form 4: Boston Scientific SVP, GC and Corp. Secretary Vance R. Brown Executes Stock Options and Sells Shares

Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, exercised stock options and sold shares of common stock on May 21 and 22, 2024, according to a Form 4 filing with the SEC.

Summary

• Vance R. Brown, a senior officer at Boston Scientific, engaged in transactions involving the company's common stock on May 21 and May 22, 2024.
• These transactions involved the exercise of stock options and the subsequent sale of shares.
• On May 21, 2024, Brown exercised options to acquire 18,037 shares at a price of $24.55 per share and sold the same amount of shares at a weighted average price of $75.6005.
• On May 22, 2024, Brown exercised options to acquire 15,006 shares at a price of $27.09 per share and sold the same amount of shares at a weighted average price of $76.0118.
• The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024.
• Following these transactions, Brown directly owns 32,326 shares of Boston Scientific common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.

Industry Context

Insider transactions are routinely monitored and reported to the SEC, providing transparency into the actions of company executives. The use of a pre-established Rule 10b5-1 trading plan is a common practice to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry often include stock options as a significant component.
• The exercise of stock options and subsequent sale of shares is a common wealth management strategy among executives at companies like Medtronic, Abbott, and Stryker.
• Rule 10b5-1 trading plans are widely used by corporate insiders across various industries to schedule stock transactions in advance and demonstrate compliance with insider trading regulations.

Stakeholder Impact

• The transactions have a minimal direct impact on shareholders, as they represent a small portion of the overall outstanding shares.
• The use of a Rule 10b5-1 trading plan provides transparency and helps ensure fair trading practices, which benefits all stakeholders.

Key Dates